Context Therapeutics Inc. (CNTX)
0.85
0.01 (0.82%)
At close: Apr 21, 2025, 3:59 PM
0.83
-2.49%
Pre-market: Apr 22, 2025, 04:00 AM EDT
0.82% (1D)
| Bid | 0.77 |
| Market Cap | 76.28M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -26.73M |
| EPS (ttm) | -0.46 |
| PE Ratio (ttm) | -1.85 |
| Forward PE | -2.48 |
| Analyst | Buy |
| Ask | 0.88 |
| Volume | 92,561 |
| Avg. Volume (20D) | 158,696 |
| Open | 0.69 |
| Previous Close | 0.84 |
| Day's Range | 0.79 - 0.85 |
| 52-Week Range | 0.55 - 2.75 |
| Beta | 2.18 |
About CNTX
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also dev...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 20, 2021
Employees 12
Stock Exchange NASDAQ
Ticker Symbol CNTX
Analyst Forecast
According to 6 analyst ratings, the average rating for CNTX stock is "Buy." The 12-month stock price forecast is $5, which is an increase of 488.03% from the latest price.
Stock Forecasts
